UPDATED WEEKLY

Frontier biomedicine and deals, every week

From breakthrough paper to licensing deal. Weekly briefs on the research reshaping drug discovery, and the deals and conferences where it changes hands.

We’ll email you a confirmation link. Free; one-click unsubscribe any time.

THIS WEEK'S LEAD · TUMOR IMMUNOLOGY & CELL THERAPY

Personalized neoantigen vaccine in ovarian cancer, phase 1: feasible, with escape pointing to antigen presentation

The single-arm phase 1 NeoVax trial gave platinum-sensitive high-grade ovarian cancer patients a personalized synthetic long-peptide vaccine after standard chemotherapy, adding nivolumab from week 14. 9 of 12 (75%) first-relapse patients were vaccinated, with no unexpected safety signals; 8 of 10 vaccinated patients mounted vaccine-specific T-cell responses. Progression tracked with HLA loss, a JAK1 structural variant and loss of vaccine targets. Small, uncontrolled study; efficacy is not established.

Oct 14, 2026 · Source: Nature MedicineRead the analysis →

Latest science

All science →
INLIGHT ORIGINAL RESEARCH · 12-PART SERIES

China Biopharma Out-Licensing Deal Survey (2026)

Analysis of 237 China-origin out-licensing and related deals. Median cash upfront $55m, 4.9% of headline value; 25 public agreements coded clause by clause. Covers deal structure, milestone realization and NewCo equity.

Briefs

1 item · based on abstracts
  • AI-generated illustration
    Nucleic acid & gene therapy

    Compact Cas12m variant enables multiplexed gene activation from one AAV

    Nature Biotechnology · Oct 28, 2026 · doi:10.1038/s41587-026-03352-5

    Engineered denCas12m in the smCRISPRa platform processes a multi-gRNA array from a single transcript; one all-in-one AAV activated up to six genes with eight crRNAs in mice. Phenotypic rescue was shown in mouse models of Duchenne muscular dystrophy and Scn1a haploinsufficiency (abstract only).

    基于摘要 / Based on abstract · Generated:

China out-licensing tracker

Annual tally →
157deals in 2025
$135.7Btotal value, 2025
~5%paid upfront ($7.0B)

Bar length = total deal value; dark segment = combined upfront payments. Data: DIA Global Forum, March 2026. Most of the headline value is milestones that are paid only if development succeeds. Every deal we track, with sources →

Latest deals & data

All deals →

Pfizer in-licenses three preclinical in vivo CAR-T programs from Starna, with $330M upfront

$330M upfront
Licensing

Spruce splits Harbour-originated CRHX-101 into Adrenyx, targeting a first-half 2027 Nasdaq listing

$5M initial convertible note
NewCo

Marrow Therapeutics launches with $173M in Series A and B financing

$173M
Financing

FDA launches Global Reliance Disclosure Program to share redacted approval reviews with foreign regulators

No deal value
Regulatory

Johnson & Johnson to acquire Ollin Biosciences; lead asset is Innovent-originated IBI324

$2.2B upfront
M&A

Lilly agrees to acquire Calytrix Bio for up to $1.5B in cash; upfront not separately disclosed

Up to $1.5B cash
M&A

Seawolf Therapeutics debuts with $100M in financing and a Sanofi collaboration

$100M financing
FinancingLicensing

Sinotau-B (09941.HK) opens Hong Kong IPO; trading expected November 24

About HK$341M–$446M
Financing

Phrontline Biopharma raises about $40M in a Series A

About $40M
Financing

Upcoming conferences

All events →

Working on an asset or a landscape report? See Services →

One email a week

New science briefs and cross-border licensing & M&A deals, each with a link to the original source. Free; unsubscribe any time.

Subscribe

Sources cited in our briefs. Science: Nature ×13, Nature Portfolio ×22, Cell Press ×2, bioRxiv ×6, Taylor & Francis ×1, JCI ×1, Company of Biologists ×1, NEJM ×1. Deals: BioPharma Dive ×4, AllSci ×3, Fierce Biotech ×3, BioSpace ×2, BioPharm International ×1, BioXconomy ×1, DIA Global Forum ×1, HKEXnews ×7, SEC EDGAR ×2, PR Newswire ×6, GlobeNewswire ×2, Business Wire ×1, Company press releases ×12. Counts = briefs or citations per source; every item links to its original.